A revolutionary way of making stem cells claimed last year by Japanese and US researchers never existed in the first place. That is the conclusion of two papers1, 2 published on 23 September inNature — the same journal that published the original, ill-fated papers early last year. Multiple labs conclude that the seemingly miraculous results originated from contamination with ordinary stem cells.
For the full article: “Failed replications put STAP stem-cell claims to rest”
“Failure to replicate the STAP cell phenomenon”
“STAP cells are derived from ES cells”
Image source: http://www.nature.com/news/stap-1.15332
Posted in STAP
Tagged STAP, Stem cells
Anish Sen Majumdar is a veteran stem cell scientist, he has trained hundreds of scientists and has been a member of various international societies that are involved in globalizing scientific & clinical research using stem cells and formulating international policies for regulating the use of stem cells in human disease conditions. His talk centers on curing diabetes and critical limb ischemia, two diseases prevalent in India.
He earned his PhD in biochemistry, moved to USA to complete his postdoctoral studies and joined Stanford University School of’medicine to pursue research on types of progenitor and mature immune cells in the context of health and disease states of the body. During his career, he has trained hundreds of scientists and has been a member of various international societies that are involved in globalizing scientific and clinical research using stem cells and formulating international policies for regulating the use of stem cells in human disease conditions.
This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at http://ted.com/tedx
Clinics around China have been ignoring government regulations and warnings from the scientific community for years. They offered desperate patients costly and, according to experts, probably ineffective treatments. These were often labelled as clinical trials as a cover to charge patients. Other countries have experienced similar problems. Now, new regulations in China will hopefully end this unethical behaviour.
Read more: China announces stem-cell rules
The research of Dr. Clevers is focused on healthy and diseased intestines. He has discovered and delineated some of the most fundamental molecular signaling processes that drive normal development of the gut and linked these to diseases such as cancer. In recent years he was the first, and foremost, discoverer of the stem cell of the intestine. He succeeded in growing “mini intestines” in cell culture dishes. Professor Clevers’ scientific contributions can be counted among the most important in biomedicine of his generation and have a fundamental impact on both regenerative medicine and cancer treatment. In this talk, Prof. Clevers describes his research goals and some of his results.
In this talk, Stephen Huhn, the Vice President for Clinical Research and Chief Medical Officer of StemCells Inc. provides a brief update on the clinical programs of the company.
The potential clinical applications of embryonic and adult stem cells are limitless, but major barriers in developing new therapies involving stem cells are obtaining and manipulating well-characterized cells in culture. In this webinar, Dr. Kevin Eggan (HHMI, Harvard Stem Cell Institute) will discuss some of the state-of-the-art methods for working with stem cells, along with the scientific challenges encountered with these methods. He will also present examples of the use of these techniques from his own work involving both human embryonic stem cells and iPS cells in the study of nervous system disorders, such as ALS, and for the development of new treatments.
Abstract: Duchenne muscular dystrophy is a genetically determined X-linked disease and the most common, progressive pediatric muscle disorder. For decades, research has been conducted to find an effective therapy. This review presents current therapeutic methods for Duchenne muscular dystrophy, based on scientific articles in English published mainly in the period 2000 to 2014. We used the PubMed database to identify and review the most important studies. An analysis of contemporary studies of stem cell therapy and the use of granulocyte colony-stimulating factor (G-CSF) in muscular dystrophy was performed.
Paper: “Duchenne muscular dystrophy: current cell therapies”